Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968194 | 0.85 | LMNA (0.39) | LMNAMAPTPOLBGAATSHR | |
| SCHEMBL3987656 | 0.83 | MAPK1 (0.41) | LMNAMAPTPOLBGAATSHR | |
| SCHEMBL3987948 | 0.81 | MAPT (0.44) | LMNAMAPTPOLBGAATSHR | |
| SCHEMBL3987971 | 0.81 | MAPT (0.44) | LMNAMAPTPOLBGAATSHR | |
| SCHEMBL3988144 | 0.79 | MAPK1 (0.41) | LMNAMAPTMAPK1HTTHSD17B10 | |
| SCHEMBL3986313 | 0.79 | MAPK1 (0.42) | LMNAMAPTPOLBGAATSHR | |
| SCHEMBL3992089 | 0.76 | MAPT (0.41) | LMNAMAPTPOLBGAAMAPK1 | |
| SCHEMBL3986411 | 0.76 | KDM4E (0.30) | ALDH1A1KDM4EHPGD | |
| SCHEMBL3990171 | 0.74 | HRH4 (0.38) | LMNAHRH4HRH3ACHE | |
| SCHEMBL3993185 | 0.74 | ALDH1A1 (0.34) | MAPTNPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | claimed |
| EP-1663993-B1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-12 | — | — | EP | claimed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | claimed |
| JP-2007504176-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1663993-A1 | GUANIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005023781-A1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-03-17 | — | — | WO | claimed |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-09-03 | — | — | US | disclosed |
| WO-2015120446-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULENESS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-08-13 | — | — | WO | disclosed |
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | disclosed |
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | disclosed |
| US-7544691-B2 | Guanidine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-06-09 | — | — | US | disclosed |
| EP-1663993-B1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123510-A1 | Guanidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-05-31 | — | — | US | disclosed |
| EP-1663993-A1 | GUANIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023781-A1 | GUANIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123510-A1 | Guanidine derivatives | NPFFR1, NPFFR2, OGFR | LMNA 3425/4885MAPT 1674/4885POLB 1126/4885 |
| US-20150246140-A1 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS | HCRTR2, HCRTR1, NPSR1 | LMNA 866/4885MAPT 2646/4885POLB 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.